Rebecca McQualter
CEO
Chimeric Therapeutics
Chimeric Therapeutics develops a diversified portfolio of cell therapy assets, including autologous CAR T and allogeneic NK cell therapies, for oncology indications. The company is advancing multiple first-in-class and best-in-class candidates through Phase 1/1b clinical trials. Their focus is on driving agile development and optimization to bring transformative cell therapies to patients with advanced cancer.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Traditional cancer therapies often have limited effectiveness against solid tumors, leading to poor outcomes for patients with advanced disease. Current treatments may not specifically target cancer cells, resulting in damage to healthy tissues and significant side effects. The need for more targeted and effective therapies remains a critical challenge in oncology.
Solution
Chimeric Therapeutics is developing a portfolio of cell therapies, including CAR T-cell and NK-cell therapies, designed to target solid tumors with greater precision. The company's CAR T-cell therapies utilize engineered T cells to recognize and destroy cancer cells expressing specific antigens. Its NK-cell therapies harness the innate ability of natural killer cells to identify and eliminate cancerous cells, offering a potential "off-the-shelf" allogeneic treatment option. Chimeric's therapies incorporate novel targeting domains, such as Chlorotoxin (CLTX) derived from scorpion venom, to enhance tumor specificity and improve treatment outcomes. These cell therapies are currently in Phase 1/1b clinical trials, evaluating their safety and efficacy in various oncology indications.
Target Audience
The primary target audience includes patients with advanced solid tumors and hematologic malignancies who have limited treatment options, as well as clinicians and researchers in the field of oncology seeking innovative cell-based therapies.
Features
- CLTX CAR T (CHM 1101): Utilizes Chlorotoxin, a peptide derived from deathstalker scorpion venom, to target glioblastoma cells expressing membrane-bound matrix metalloprotease 2.
- CDH17 CAR T (CHM 2101): Targets CDH17, an antigen expressed in neuroendocrine tumors and gastrointestinal cancers, with a 3rd generation CAR T-cell construct.
- CORE-NK platform: An allogeneic NK-cell therapy platform designed for "off-the-shelf" use, engineered to enhance the activity and robustness of natural killer cells.
- Next-generation CORE-NK platform: Integrates additional activation and expansion features to further optimize the cancer-fighting power of CORE-NK cells.
- Preclinical studies demonstrate potent anti-tumor activity and specificity of CAR T-cell therapies, with no off-tumor recognition of normal human or murine cells.
- Clinical trials are ongoing to assess the safety and efficacy of Chimeric's cell therapies in patients with recurrent or progressive solid tumors and blood cancers.